Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06961604 · ClinicalTrials.gov registry record · Early Phase 1
A Novel Method for Determination of Thromboembolic Stroke Origin
A Early Phase 1 study, sponsored by Atlantic Health System.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT06961604 is a Early Phase 1 study that has not yet begun recruiting, run by Atlantic Health System. The registered enrollment target is 20 participants.
The verdict
NCT06961604, a Early Phase 1 study, has not yet begun recruiting, sponsored by Atlantic Health System.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Rupture of vulnerable carotid, vertebral, and intracranial arterial plaques results in thromboembolic stroke. Identification of these culprit lesions is an important component of post-stroke care. This study seeks to test the feasibility of NaF PET-CT to detect these plaques and alter patient care. Prior studies have shown a high degree of correlation between NaF PET+ lesions and high-risk plaque features on high resolution MRI, including mirocalcification, necrosis, and ulceration.
Interventions
- DRUG NaF PET-CT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-06-01 |
| Est. Completion | 2026-05-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06961604
The ClinicalTrials.gov registry entry for NCT06961604 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atlantic Health System, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NaF PET-CT is the first listed.
NCT06961604 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06961604 about?
NCT06961604 is a clinical study titled "A Novel Method for Determination of Thromboembolic Stroke Origin". Rupture of vulnerable carotid, vertebral, and intracranial arterial plaques results in thromboembolic stroke. Identification of these culprit lesions is an important component of post-stroke care. This study seeks to test the feasibility of NaF PET-CT to detect these plaques and alter patient care. ...
What is the current status of trial NCT06961604?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2025-06-01. Estimated completion is 2026-05-31.
What interventions are being tested in trial NCT06961604?
The interventions under investigation include: NaF PET-CT (DRUG).
Who is sponsoring clinical trial NCT06961604?
This trial is sponsored by Atlantic Health System, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.